Antibody response to SARS‐CoV‐2 vaccination is extremely vivacious in subjects with previous SARS‐CoV‐2 infection

• Published in: Journal of medical virology Vol. 93; no. 7; pp. 4612 - 4615
• Main Authors: Callegaro, Annapaola, Borleri, Daniela, Farina, Claudio, Napolitano, Gavino, Valenti, Daniela, Rizzi, Marco, Maggiolo, Franco
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.07.2021; John Wiley and Sons Inc
• Subjects: Adult; Antibodies; Antibodies, Viral - blood; Antibodies, Viral - immunology; Antibody response; Asymptomatic infection; Asymptomatic Infections; Confidence intervals; Coronaviruses; COVID-19; COVID-19 - diagnosis; COVID-19 - immunology; COVID-19 - prevention & control; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - adverse effects; COVID-19 Vaccines - immunology; Dosage; Female; Health Personnel; Humans; humoral immunity; Immunity; Immunization Schedule; Immunization, Secondary; Immunoassay; Infections; Injection; Male; Medical personnel; Middle Aged; mRNA; mRNA Vaccines; Pandemics; Respiratory diseases; SARS-CoV-2 - immunology; SARS-CoV-2 - isolation & purification; SARS‐CoV‐2; Schedules; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Short Communication; Short Communications; Spike Glycoprotein, Coronavirus - immunology; spike m‐RNA vaccine; spike RBD; Vaccination; Vaccines; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - adverse effects; Vaccines, Synthetic - immunology; Viral diseases; Virology; COVID-19; SARS-CoV-2; humoral immunity; spike m-RNA vaccine; spike RBD
• ISSN: 0146-6615; 1096-9071; 1096-9071
• DOI: 10.1002/jmv.26982

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic calls for rapid actions, now principally oriented to a world‐wide vaccination campaign. In this study we verified if, in individuals with a previous SARS‐CoV‐2 infection, a single dose of messenger RNA (mRNA) vaccine would be immunologically equivalent to a full vaccine schedule in naïve individuals. Health care workers (184) with a previous SARS‐CoV‐2 infection were sampled soon before the second dose of vaccine and between 7 and 10 days after the second dose, the last sampling time was applied to SARS‐CoV‐2 naïve individuals, too. Antibodies against SARS‐CoV‐2 were measured using Elecsys Anti‐SARS‐CoV‐2 S immunoassay. The study was powered for non‐inferiority. We used non parametric tests and Pearson correlation test to perform inferential analysis. After a single vaccine injection, the median titer of specific antibodies in individuals with previous coronavirus disease 2019 was 30.527 U/ml (interquartile range [IQR]: 19.992–39.288) and in subjects with previous SARS‐CoV‐2 asymptomatic infection was 19.367.5 U/ml (IQR: 14.688–31.353) (p = .032). Both results were far above the median titer in naïve individuals after a full vaccination schedule: 1974.5 U/ml (IQR: 895–3455) (p < .0001). Adverse events after vaccine injection were more frequent after the second dose of vaccine (mean: 0.95; 95% confidence interval [CI]: 0.75–1.14 vs. mean: 1.91; 95% CI: 1.63–2.19) (p < .0001) and in exposed compared to naïve (mean: 1.63; 95% CI: 1.28–1.98 vs. mean: 2.35; 95% CI: 1.87–2.82) (p = .015). In SARS‐CoV‐2 naturally infected individuals a single mRNA vaccine dose seems sufficient to reach immunity. Modifying current dosing schedules would speed‐up vaccination campaigns. Highlights 1) Individuals COVID 19 positive shows a single dose antibody titers 10 fold higher than naive individuals with full vaccination schedule 2) In SARS‐CoV‐2 naturally infected individuals a single mRNA vaccine dose seems sufficient to reach immunity.